Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

被引：10
|
作者：
Kondagunta, GV
Bacik, J
Schwartz, L
Sheinfeld, J
Bajorin, D
Vuky, J
Marion, S
Mazumdar, M
Bosl, GJ
Motzer, RJ
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Biostat Epidemiol & Stat, New York, NY 10021 USA
来源：
INVESTIGATIONAL NEW DRUGS | 2004年 / 22卷 / 02期
关键词：
temozolomide; germ cell tumor; nonseminoma; cisplatin-refractory; phase II;
D O I：
10.1023/B:DRUG.0000011794.21608.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m(2)/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.
引用
收藏
页码：177 / 179
页数：3
相关论文
共 50 条
  • [1] Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors
    G. Varuni Kondagunta
    Jennifer Bacik
    Lawrence Schwartz
    Joel Sheinfeld
    Dean Bajorin
    Jacqueline Vuky
    Stephanie Marion
    Madhu Mazumdar
    George J. Bosl
    Robert J. Motzer
    Investigational New Drugs, 2004, 22 : 177 - 179
  • [2] Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors
    Vuky, J
    McCaffrey, J
    Ginsberg, M
    Mariani, T
    Bajorin, DF
    Bosl, GJ
    Motzer, RJ
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (03) : 265 - 267
  • [3] Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors
    Feldman, Darren R.
    Kondagunta, G. Varuni
    Ginsberg, Michelle S.
    Ishill, Nicole
    Patil, Sujata
    Cestaro, John
    Obbens, Eugenie
    Sheinfeld, Joel
    Bosl, George J.
    Motzer, Robert J.
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (05) : 487 - 490
  • [4] Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors
    Darren R. Feldman
    G. Varuni Kondagunta
    Michelle S. Ginsberg
    Nicole Ishill
    Sujata Patil
    John Cestaro
    Eugenie Obbens
    Joel Sheinfeld
    George J. Bosl
    Robert J. Motzer
    Investigational New Drugs, 2007, 25 : 487 - 490
  • [5] Phase II Trial of Pyrazoloacridine in Patients with Cisplatin-Refractory Germ Cell Tumors
    Jacqueline Vuky
    John McCaffrey
    Michelle Ginsberg
    Tania Mariani
    Dean F. Bajorin
    George J. Bosl
    Robert J. Motzer
    Investigational New Drugs, 2000, 18 : 265 - 267
  • [6] PHASE-II TRIAL OF TOPOTECAN IN PATIENTS WITH CISPLATIN-REFRACTORY GERM-CELL TUMORS
    PUC, HS
    BAJORIN, DF
    BOSL, GJ
    AMSTERDAM, A
    MOTZER, RJ
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (02) : 163 - 165
  • [7] Treatment of patients with cisplatin-refractory germ cell tumors
    Koychev, D.
    Honecker, F.
    Bokemeyer, C.
    Albers, P.
    ONKOLOGE, 2013, 19 (07): : 564 - 567
  • [8] Sunitinib in Patients with Cisplatin-Refractory Germ Cell Tumors
    Reckova, Maria
    Mego, Michel
    Sycova-Mila, Zuzana
    Obertova, Jana
    Svetlovska, Dana
    Mardiak, Jozef
    ONKOLOGIE, 2012, 35 (7-8): : 455 - 456
  • [9] Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study
    Pectasides, D
    Pectasides, M
    Farmakis, D
    Aravantinos, G
    Nikolaou, M
    Koumpou, M
    Gaglia, A
    Kostopoulou, V
    Mylonakis, N
    Skarlos, D
    ANNALS OF ONCOLOGY, 2004, 15 (03) : 493 - 497
  • [10] An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors
    Oechsle, Karin
    Honecker, Friedemann
    Kollmannsberger, Christian
    Rick, Oliver
    Gruenwald, Victor
    Mayer, Frank
    Hartmann, Joerg T.
    Bokemeyer, Carsten
    ANTI-CANCER DRUGS, 2007, 18 (03) : 273 - 276
12345